vs
Crane NXT, Co.（CXT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Crane NXT, Co.的1.3倍（$622.0M vs $476.9M），Royalty Pharma plc净利率更高（34.4% vs 10.0%，领先24.5%），Crane NXT, Co.同比增速更快（19.5% vs 4.8%），过去两年Crane NXT, Co.的营收复合增速更高（23.3% vs 4.6%）
Crane NXT是一家总部位于美国康涅狄格州斯坦福德的工业产品企业，由理查德·特勒·克莱恩于1855年创立。曾是美国头部卫浴配件制造商，1990年出售卫浴业务后，自1960年起逐步转型为多元化控股集团，目前核心业务涵盖航空航天与电子、工程材料、流体处理、控制设备四大板块，服务化工等多个行业领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CXT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$476.9M
营收增速更快
CXT
高出14.7%
4.8%
净利率更高
RPRX
高出24.5%
10.0%
两年增速更快
CXT
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $476.9M | $622.0M |
| 净利润 | $47.5M | $214.2M |
| 毛利率 | 42.4% | — |
| 营业利润率 | 16.7% | 62.4% |
| 净利率 | 10.0% | 34.4% |
| 营收同比 | 19.5% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $0.82 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXTRPRX
| Q4 25 | $476.9M | $622.0M | ||
| Q3 25 | $445.1M | $609.3M | ||
| Q2 25 | $404.4M | $578.7M | ||
| Q1 25 | $330.3M | $568.2M | ||
| Q4 24 | $399.1M | $593.6M | ||
| Q3 24 | $403.5M | $564.7M | ||
| Q2 24 | $370.6M | $537.3M | ||
| Q1 24 | $313.6M | $568.0M |
净利润CXTRPRX
| Q4 25 | $47.5M | $214.2M | ||
| Q3 25 | $50.5M | $288.2M | ||
| Q2 25 | $24.9M | $30.2M | ||
| Q1 25 | $21.7M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $47.1M | $544.0M | ||
| Q2 24 | $41.6M | $102.0M | ||
| Q1 24 | $37.8M | $4.8M |
毛利率CXTRPRX
| Q4 25 | 42.4% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 41.7% | — | ||
| Q1 25 | 42.4% | — | ||
| Q4 24 | 45.2% | — | ||
| Q3 24 | 42.5% | — | ||
| Q2 24 | 43.4% | — | ||
| Q1 24 | 48.6% | — |
营业利润率CXTRPRX
| Q4 25 | 16.7% | 62.4% | ||
| Q3 25 | 18.4% | 70.1% | ||
| Q2 25 | 11.8% | 36.3% | ||
| Q1 25 | 11.3% | 94.0% | ||
| Q4 24 | 17.7% | 60.9% | ||
| Q3 24 | 18.6% | — | ||
| Q2 24 | 18.2% | 50.2% | ||
| Q1 24 | 17.7% | -13.0% |
净利率CXTRPRX
| Q4 25 | 10.0% | 34.4% | ||
| Q3 25 | 11.3% | 47.3% | ||
| Q2 25 | 6.2% | 5.2% | ||
| Q1 25 | 6.6% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 11.7% | 96.3% | ||
| Q2 24 | 11.2% | 19.0% | ||
| Q1 24 | 12.1% | 0.8% |
每股收益（稀释后）CXTRPRX
| Q4 25 | $0.82 | $0.49 | ||
| Q3 25 | $0.87 | $0.67 | ||
| Q2 25 | $0.43 | $0.07 | ||
| Q1 25 | $0.38 | $0.55 | ||
| Q4 24 | $1.00 | $0.46 | ||
| Q3 24 | $0.81 | $1.21 | ||
| Q2 24 | $0.72 | $0.23 | ||
| Q1 24 | $0.66 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.8M | $618.7M |
| 总债务越低越好 | $1.0B | $9.0B |
| 股东权益账面价值 | $1.3B | $9.7B |
| 总资产 | $3.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.80× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CXTRPRX
| Q4 25 | $233.8M | $618.7M | ||
| Q3 25 | $182.4M | $938.9M | ||
| Q2 25 | $152.5M | $631.9M | ||
| Q1 25 | $173.8M | $1.1B | ||
| Q4 24 | $165.8M | $929.0M | ||
| Q3 24 | $165.1M | $950.1M | ||
| Q2 24 | $175.5M | $1.8B | ||
| Q1 24 | $220.6M | $843.0M |
总债务CXTRPRX
| Q4 25 | $1.0B | $9.0B | ||
| Q3 25 | $834.3M | $8.9B | ||
| Q2 25 | $861.8M | $8.0B | ||
| Q1 25 | $541.1M | $7.6B | ||
| Q4 24 | $540.6M | $7.6B | ||
| Q3 24 | $638.2M | $7.6B | ||
| Q2 24 | $638.9M | $7.6B | ||
| Q1 24 | $639.6M | $6.1B |
股东权益CXTRPRX
| Q4 25 | $1.3B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $989.8M | $9.8B | ||
| Q1 24 | $964.1M | $9.9B |
总资产CXTRPRX
| Q4 25 | $3.1B | $19.6B | ||
| Q3 25 | $2.9B | $19.3B | ||
| Q2 25 | $2.9B | $18.3B | ||
| Q1 25 | $2.4B | $17.6B | ||
| Q4 24 | $2.4B | $18.2B | ||
| Q3 24 | $2.4B | $18.0B | ||
| Q2 24 | $2.4B | $17.7B | ||
| Q1 24 | $2.1B | $16.1B |
负债/权益比CXTRPRX
| Q4 25 | 0.80× | 0.92× | ||
| Q3 25 | 0.69× | 0.93× | ||
| Q2 25 | 0.73× | 0.84× | ||
| Q1 25 | 0.49× | 0.78× | ||
| Q4 24 | 0.51× | 0.74× | ||
| Q3 24 | 0.60× | 0.74× | ||
| Q2 24 | 0.65× | 0.78× | ||
| Q1 24 | 0.66× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $105.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 2.23× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CXTRPRX
| Q4 25 | $105.8M | $827.1M | ||
| Q3 25 | $92.0M | $702.6M | ||
| Q2 25 | $62.8M | $364.0M | ||
| Q1 25 | $-19.1M | $596.1M | ||
| Q4 24 | $81.1M | $742.5M | ||
| Q3 24 | $66.7M | $703.6M | ||
| Q2 24 | $56.8M | $658.2M | ||
| Q1 24 | $9.5M | $664.6M |
自由现金流CXTRPRX
| Q4 25 | — | — | ||
| Q3 25 | $78.7M | — | ||
| Q2 25 | $55.8M | — | ||
| Q1 25 | $-32.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $53.5M | — | ||
| Q2 24 | $47.9M | — | ||
| Q1 24 | $-3.0M | — |
自由现金流率CXTRPRX
| Q4 25 | — | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 13.8% | — | ||
| Q1 25 | -9.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.9% | — | ||
| Q1 24 | -1.0% | — |
资本支出强度CXTRPRX
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 4.0% | — |
现金转化率CXTRPRX
| Q4 25 | 2.23× | 3.86× | ||
| Q3 25 | 1.82× | 2.44× | ||
| Q2 25 | 2.52× | 12.06× | ||
| Q1 25 | -0.88× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.42× | 1.29× | ||
| Q2 24 | 1.37× | 6.45× | ||
| Q1 24 | 0.25× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXT
| Other | $260.9M | 55% |
| Products | $181.1M | 38% |
| Services | $34.9M | 7% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
